Peg-filgrastim and cabazitaxel in prostate cancer patients

Giuseppe Di Lorenzo, Carmine D'aniello, Carlo Buonerba, Piera Federico, Pasquale Rescigno, Livio Puglia, Matteo Ferro, Davide Bosso, Carla Cavaliere, Giovannella Palmieri, Guru Sonpavde, Sabino De Placido

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

To determine the impact of prophylaxis with granulocyte-colony stimulating growth factor (G-CSF) on the risk of febrile neutropenia in a cohort of patients enrolled at the University Federico II of Naples and treated with cabazitaxel for metastatic castration-resistant prostate cancer (mCRPC). We carried out a retrospective review of prospectively collected data of patients enrolled at our institution in a compassionate-use programme with cabazitaxel, aimed at providing early access to the drug before its commercial availability in mCRPC patients. Besides baseline clinical and demographic characteristics, data on treatment efficacy and toxicity, as well as those on the use of G-CSF per patient per cycle were extracted. Progression-free survival and overall survival were calculated using the Kaplan-Meier method. Fisher's exact test was used to explore a relationship between a single event of grade 3 or more neutropenia or febrile neutropenia and previous use of G-CSF. Univariate analysis was carried out to evaluate predictors of grade 3 or more neutropenia and/or febrile neutropenia. Of 34 patients enrolled at our institution from December 2010 to December 2011, 32 had received at least one dose of cabazitaxel and were included in the analysis. Patients received a median of 10 cabazitaxel cycles. Grade 3 or more neutropenia was common, occurring in 64.5% of patients. Three patients (9.3%) developed febrile neutropenia. Twenty-seven patients received prophylaxis with G-CSF during at least one cycle using peg-filgrastim. The risk of grade 3 or more neutropenia and/or febrile neutropenia per patient and per cycle was seven times lower when G-CSF was used. Baseline neutrophil count of less than 4570/mm was the strongest predictor of grade 3 or more neutropenia and/or febrile neutropenia. No toxic death was reported. Only one patient discontinued cabazitaxel because of an adverse event. Our analysis suggests that prophylaxis with peg-filgrastim may considerably reduce the incidence of grade 3 or more neutropenia and, possibly, of febrile neutropenia in mCRPC patients treated with cabazitaxel. Further analyses involving a larger population are warranted to confirm our results.

Original languageEnglish
Pages (from-to)84-89
Number of pages6
JournalAnti-Cancer Drugs
Volume24
Issue number1
DOIs
Publication statusPublished - Jan 2013

Fingerprint

Prostatic Neoplasms
Febrile Neutropenia
Neutropenia
Granulocyte Colony-Stimulating Factor
Intercellular Signaling Peptides and Proteins
Castration
cabazitaxel
Filgrastim
Compassionate Use Trials
Poisons
Disease-Free Survival
Neutrophils
Demography
Survival
Incidence

Keywords

  • Cabazitaxel
  • Chemotherapy
  • Peg-filgrastim
  • Prostate cancer

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Cancer Research
  • Oncology

Cite this

Di Lorenzo, G., D'aniello, C., Buonerba, C., Federico, P., Rescigno, P., Puglia, L., ... De Placido, S. (2013). Peg-filgrastim and cabazitaxel in prostate cancer patients. Anti-Cancer Drugs, 24(1), 84-89. https://doi.org/10.1097/CAD.0b013e32835a56bc

Peg-filgrastim and cabazitaxel in prostate cancer patients. / Di Lorenzo, Giuseppe; D'aniello, Carmine; Buonerba, Carlo; Federico, Piera; Rescigno, Pasquale; Puglia, Livio; Ferro, Matteo; Bosso, Davide; Cavaliere, Carla; Palmieri, Giovannella; Sonpavde, Guru; De Placido, Sabino.

In: Anti-Cancer Drugs, Vol. 24, No. 1, 01.2013, p. 84-89.

Research output: Contribution to journalArticle

Di Lorenzo, G, D'aniello, C, Buonerba, C, Federico, P, Rescigno, P, Puglia, L, Ferro, M, Bosso, D, Cavaliere, C, Palmieri, G, Sonpavde, G & De Placido, S 2013, 'Peg-filgrastim and cabazitaxel in prostate cancer patients', Anti-Cancer Drugs, vol. 24, no. 1, pp. 84-89. https://doi.org/10.1097/CAD.0b013e32835a56bc
Di Lorenzo G, D'aniello C, Buonerba C, Federico P, Rescigno P, Puglia L et al. Peg-filgrastim and cabazitaxel in prostate cancer patients. Anti-Cancer Drugs. 2013 Jan;24(1):84-89. https://doi.org/10.1097/CAD.0b013e32835a56bc
Di Lorenzo, Giuseppe ; D'aniello, Carmine ; Buonerba, Carlo ; Federico, Piera ; Rescigno, Pasquale ; Puglia, Livio ; Ferro, Matteo ; Bosso, Davide ; Cavaliere, Carla ; Palmieri, Giovannella ; Sonpavde, Guru ; De Placido, Sabino. / Peg-filgrastim and cabazitaxel in prostate cancer patients. In: Anti-Cancer Drugs. 2013 ; Vol. 24, No. 1. pp. 84-89.
@article{61ca8c5ae82f430f8a09269b6944a66e,
title = "Peg-filgrastim and cabazitaxel in prostate cancer patients",
abstract = "To determine the impact of prophylaxis with granulocyte-colony stimulating growth factor (G-CSF) on the risk of febrile neutropenia in a cohort of patients enrolled at the University Federico II of Naples and treated with cabazitaxel for metastatic castration-resistant prostate cancer (mCRPC). We carried out a retrospective review of prospectively collected data of patients enrolled at our institution in a compassionate-use programme with cabazitaxel, aimed at providing early access to the drug before its commercial availability in mCRPC patients. Besides baseline clinical and demographic characteristics, data on treatment efficacy and toxicity, as well as those on the use of G-CSF per patient per cycle were extracted. Progression-free survival and overall survival were calculated using the Kaplan-Meier method. Fisher's exact test was used to explore a relationship between a single event of grade 3 or more neutropenia or febrile neutropenia and previous use of G-CSF. Univariate analysis was carried out to evaluate predictors of grade 3 or more neutropenia and/or febrile neutropenia. Of 34 patients enrolled at our institution from December 2010 to December 2011, 32 had received at least one dose of cabazitaxel and were included in the analysis. Patients received a median of 10 cabazitaxel cycles. Grade 3 or more neutropenia was common, occurring in 64.5{\%} of patients. Three patients (9.3{\%}) developed febrile neutropenia. Twenty-seven patients received prophylaxis with G-CSF during at least one cycle using peg-filgrastim. The risk of grade 3 or more neutropenia and/or febrile neutropenia per patient and per cycle was seven times lower when G-CSF was used. Baseline neutrophil count of less than 4570/mm was the strongest predictor of grade 3 or more neutropenia and/or febrile neutropenia. No toxic death was reported. Only one patient discontinued cabazitaxel because of an adverse event. Our analysis suggests that prophylaxis with peg-filgrastim may considerably reduce the incidence of grade 3 or more neutropenia and, possibly, of febrile neutropenia in mCRPC patients treated with cabazitaxel. Further analyses involving a larger population are warranted to confirm our results.",
keywords = "Cabazitaxel, Chemotherapy, Peg-filgrastim, Prostate cancer",
author = "{Di Lorenzo}, Giuseppe and Carmine D'aniello and Carlo Buonerba and Piera Federico and Pasquale Rescigno and Livio Puglia and Matteo Ferro and Davide Bosso and Carla Cavaliere and Giovannella Palmieri and Guru Sonpavde and {De Placido}, Sabino",
year = "2013",
month = "1",
doi = "10.1097/CAD.0b013e32835a56bc",
language = "English",
volume = "24",
pages = "84--89",
journal = "Anti-Cancer Drugs",
issn = "0959-4973",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Peg-filgrastim and cabazitaxel in prostate cancer patients

AU - Di Lorenzo, Giuseppe

AU - D'aniello, Carmine

AU - Buonerba, Carlo

AU - Federico, Piera

AU - Rescigno, Pasquale

AU - Puglia, Livio

AU - Ferro, Matteo

AU - Bosso, Davide

AU - Cavaliere, Carla

AU - Palmieri, Giovannella

AU - Sonpavde, Guru

AU - De Placido, Sabino

PY - 2013/1

Y1 - 2013/1

N2 - To determine the impact of prophylaxis with granulocyte-colony stimulating growth factor (G-CSF) on the risk of febrile neutropenia in a cohort of patients enrolled at the University Federico II of Naples and treated with cabazitaxel for metastatic castration-resistant prostate cancer (mCRPC). We carried out a retrospective review of prospectively collected data of patients enrolled at our institution in a compassionate-use programme with cabazitaxel, aimed at providing early access to the drug before its commercial availability in mCRPC patients. Besides baseline clinical and demographic characteristics, data on treatment efficacy and toxicity, as well as those on the use of G-CSF per patient per cycle were extracted. Progression-free survival and overall survival were calculated using the Kaplan-Meier method. Fisher's exact test was used to explore a relationship between a single event of grade 3 or more neutropenia or febrile neutropenia and previous use of G-CSF. Univariate analysis was carried out to evaluate predictors of grade 3 or more neutropenia and/or febrile neutropenia. Of 34 patients enrolled at our institution from December 2010 to December 2011, 32 had received at least one dose of cabazitaxel and were included in the analysis. Patients received a median of 10 cabazitaxel cycles. Grade 3 or more neutropenia was common, occurring in 64.5% of patients. Three patients (9.3%) developed febrile neutropenia. Twenty-seven patients received prophylaxis with G-CSF during at least one cycle using peg-filgrastim. The risk of grade 3 or more neutropenia and/or febrile neutropenia per patient and per cycle was seven times lower when G-CSF was used. Baseline neutrophil count of less than 4570/mm was the strongest predictor of grade 3 or more neutropenia and/or febrile neutropenia. No toxic death was reported. Only one patient discontinued cabazitaxel because of an adverse event. Our analysis suggests that prophylaxis with peg-filgrastim may considerably reduce the incidence of grade 3 or more neutropenia and, possibly, of febrile neutropenia in mCRPC patients treated with cabazitaxel. Further analyses involving a larger population are warranted to confirm our results.

AB - To determine the impact of prophylaxis with granulocyte-colony stimulating growth factor (G-CSF) on the risk of febrile neutropenia in a cohort of patients enrolled at the University Federico II of Naples and treated with cabazitaxel for metastatic castration-resistant prostate cancer (mCRPC). We carried out a retrospective review of prospectively collected data of patients enrolled at our institution in a compassionate-use programme with cabazitaxel, aimed at providing early access to the drug before its commercial availability in mCRPC patients. Besides baseline clinical and demographic characteristics, data on treatment efficacy and toxicity, as well as those on the use of G-CSF per patient per cycle were extracted. Progression-free survival and overall survival were calculated using the Kaplan-Meier method. Fisher's exact test was used to explore a relationship between a single event of grade 3 or more neutropenia or febrile neutropenia and previous use of G-CSF. Univariate analysis was carried out to evaluate predictors of grade 3 or more neutropenia and/or febrile neutropenia. Of 34 patients enrolled at our institution from December 2010 to December 2011, 32 had received at least one dose of cabazitaxel and were included in the analysis. Patients received a median of 10 cabazitaxel cycles. Grade 3 or more neutropenia was common, occurring in 64.5% of patients. Three patients (9.3%) developed febrile neutropenia. Twenty-seven patients received prophylaxis with G-CSF during at least one cycle using peg-filgrastim. The risk of grade 3 or more neutropenia and/or febrile neutropenia per patient and per cycle was seven times lower when G-CSF was used. Baseline neutrophil count of less than 4570/mm was the strongest predictor of grade 3 or more neutropenia and/or febrile neutropenia. No toxic death was reported. Only one patient discontinued cabazitaxel because of an adverse event. Our analysis suggests that prophylaxis with peg-filgrastim may considerably reduce the incidence of grade 3 or more neutropenia and, possibly, of febrile neutropenia in mCRPC patients treated with cabazitaxel. Further analyses involving a larger population are warranted to confirm our results.

KW - Cabazitaxel

KW - Chemotherapy

KW - Peg-filgrastim

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=84870884251&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84870884251&partnerID=8YFLogxK

U2 - 10.1097/CAD.0b013e32835a56bc

DO - 10.1097/CAD.0b013e32835a56bc

M3 - Article

VL - 24

SP - 84

EP - 89

JO - Anti-Cancer Drugs

JF - Anti-Cancer Drugs

SN - 0959-4973

IS - 1

ER -